Point72 Asset Management
EGRX

Point72 Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Point72 Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,998
Closed -$38.8K – 2954
2023
Q2 		$38.8K Sell
1,998
-3,228
-62% -$76.6K ﹤0.01% 1660
2023
Q1 		$148K Buy
+5,226
New +$155K ﹤0.01% 1557
2019
Q3 		– Sell
-28,534
Closed -$1.59M – 1534
2019
Q2 		$1.59M Buy
+28,534
New +$1.49M 0.01% 692
2017
Q3 		– Sell
-45,750
Closed -$3.61M – 1093
2017
Q2 		$3.61M Buy
+45,750
New +$3.74M 0.02% 555
2016
Q3 		– Sell
-11,344
Closed -$440K – 884
2016
Q2 		$440K Sell
11,344
-188,487
-94% -$7.85M ﹤0.01% 667
2016
Q1 		$8.09M Buy
+199,831
New +$12.7M 0.06% 331

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management's EGRX Position: Q3 2023 in Review

Point72 Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 1,998 shares — an estimated $38.8K sold.

Point72 Asset Management first reported a position in EGRX in Q1 2016 and held it in 6 quarters. The position peaked at $8.09M in Q1 2016. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • Point72 Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Point72 Asset Management sold 1,998 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $38.8K.
  • Point72 Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 6 quarters.
  • Point72 Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $8.09M in Q1 2016.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Point72 Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.